Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome.
about
Proteomics analysis to reveal biological pathways and predictive proteins in the survival of high-grade serous ovarian cancerAnnexin A2 is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer.Targeting of embryonic annexin A2 expressed on ovarian and breast cancer by the novel monoclonal antibody 2448.Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma.S100A10, a novel biomarker in pancreatic ductal adenocarcinoma
P2860
Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome.
@en
Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome.
@nl
type
label
Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome.
@en
Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome.
@nl
prefLabel
Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome.
@en
Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome.
@nl
P2093
P1476
Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome.
@en
P2093
Andrew Ruszkiewicz
Carmen E Pyragius
Martin K Oehler
P304
83-95.e1-2
P356
10.1016/J.TRSL.2016.02.002
P577
2016-02-10T00:00:00Z